Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

Citations Database Search Results

Download these results to MS Excel

22 records found for:
Author = Strohbehn G
Year =

  1. Strohbehn GW, Feldman J, Popat S, Ratain MJ. Missed Opportunity for Sotorasib Dose Optimization. [Letter to the Editor]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Feb 6; JCO2402468, DOI: 10.1200/JCO-24-02468.
  2. Miller S, Jiang R, Schipper M, Fritsche LG, Strohbehn G, Wallace B, Brinzevich D, Falvello V, McMahon BH, Zamora-Resendiz R, Ramnath N, Dai X, Sankar K, Edwards DM, Allen SG, Yoo S, Crivelli S, Green MD, Bryant AK. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study. The Lancet. Oncology. 2024 Dec 1; 25(12):1666-1676.
  3. Bryant AK, Lewy JR, Bressler RD, Chopra Z, Gyori DJ, Bazzell BG, Moeller JA, Jacobson SI, Fendrick AM, Kerr EA, Ramnath N, Green MD, Hofer TP, Vaishnav P, Strohbehn GW. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system. The Lancet. Oncology. 2024 Jun 1; 25(6):802-810.
  4. Strohbehn GW, Ratain MJ. Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders. Nature reviews. Clinical oncology. 2024 May 1; 21(5):331-332.
  5. Strohbehn GW, Gyawali B. 'Contribution of component' and the perioperative immune-checkpoint inhibitor precedent. Nature reviews. Clinical oncology. 2024 Apr 1; 21(4):249-250.
  6. Strohbehn GW, Ratain MJ. Special designations and the US Food and Drug Administration's "dual mandate". Journal of the National Cancer Institute. 2024 Feb 8; 116(2):177-179.
  7. Gyawali B, Strohbehn GW. Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation? JAMA oncology. 2024 Jan 1; 10(1):41-42.
  8. Boonstra PS, Tabarrok A, Strohbehn GW. Targeted randomization dose optimization trials enable fractional dosing of scarce drugs. PLoS ONE. 2023 Oct 30; 18(10):e0287511.
  9. Edwards DM, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, Dess K, Strohbehn GW, Elliott DA, Moghanaki D, Ramnath N, Green MD, Bryant AK. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics. 2024 Mar 15; 118(4):963-970.
  10. Ratain MJ, Strohbehn GW. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? European journal of cancer (Oxford, England : 1990). 2023 Nov 1; 194:113349.
  11. Jacobson SI, Kacew AJ, Knoebel RW, Hsieh PH, Ratain MJ, Strohbehn GW. Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions. JCO oncology practice. 2023 Sep 1; 19(9):799-807.
  12. Bryant AK, Chopra Z, Edwards DM, Whalley AS, Bazzell BG, Moeller JA, Kelley MJ, Fendrick AM, Kerr EA, Ramnath N, Green MD, Hofer TP, Strohbehn GW. Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions. Health affairs (Project Hope). 2023 Jul 1; 42(7):946-955.
  13. Strohbehn GW. New strategies for dose optimization in oncology: insights from targeted small-molecule therapies for metastatic or advanced non-small cell lung cancer. Clinical advances in hematology & oncology : H&O. 2023 Apr 1; 21(4):205-208.
  14. Strohbehn GW, Lichter AS, Ratain MJ. US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 May 10; 41(14):2488-2492.
  15. Tran MC, Strohbehn GW, Karrison TG, Rouhani SJ, Segal JP, Shergill A, Hoffman PC, Patel JD, Garassino MC, Vokes EE, Bestvina CM. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clinical lung cancer. 2023 May 1; 24(3):e117-e121.
  16. Strohbehn GW, Holleman R, Burns J, Klamerus ML, Kelley MJ, Kerr EA, Ramnath N, Hofer TP. Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation. JAMA oncology. 2022 Nov 1; 8(11):1663-1667.
  17. Strohbehn G, Persad G, Parker WF, Murthy S. Dose optimisation and scarce resource allocation: two sides of the same coin. BMJ open. 2022 Oct 12; 12(10):e063436.
  18. Strohbehn GW, Sankar K, Qin A, Kalemkerian GP. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations. Expert Opinion On Pharmacotherapy. 2022 Oct 1; 23(14):1569-1575.
  19. Strohbehn GW, Saint S, Grinblatt DL, Moe J, Dhaliwal G. As the Story Unfolds. Journal of hospital medicine. 2021 Jul 1; 16(7):428-433.
  20. Strohbehn GW, Parker WF, Reid PD, Gellad WF. Socially optimal pandemic drug dosing. The Lancet. Global health. 2021 Aug 1; 9(8):e1049-e1050.
  21. Strohbehn GW, Hoffman SJK, Tokaz M, Houchens N, Slavin R, Winter S, Quinn M, Ratz D, Saint S, Chopra V, Howell JD. Visual arts in the clinical clerkship: a pilot cluster-randomized, controlled trial. BMC medical education. 2020 Nov 30; 20(1):481.
  22. Strohbehn GW, Dhaliwal G, Paulson H, Murray J, Saint S. Repetition. The New England journal of medicine. 2019 May 2; 380(18):1762-1767.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.